Aridis Pharmaceuticals (ARDS) Competitors $0.0001 0.00 (-50.00%) As of 02:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock ARDS vs. VRPX, SCPS, EVLO, CMRA, GNCAQ, GNCA, CALA, STAB, AMPE, and PXMDShould you be buying Aridis Pharmaceuticals stock or one of its competitors? The main competitors of Aridis Pharmaceuticals include Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Calithera Biosciences (CALA), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical products" industry. Aridis Pharmaceuticals vs. Its Competitors Virpax Pharmaceuticals Scopus BioPharma Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Calithera Biosciences Statera Biopharma Ampio Pharmaceuticals PaxMedica Aridis Pharmaceuticals (NASDAQ:ARDS) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation. Which has higher earnings & valuation, ARDS or VRPX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAridis PharmaceuticalsN/AN/A-$30.37MN/AN/AVirpax PharmaceuticalsN/AN/A-$15.19MN/AN/A Do insiders & institutionals hold more shares of ARDS or VRPX? 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to ARDS or VRPX? In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score. Company Overall Sentiment Aridis Pharmaceuticals Neutral Virpax Pharmaceuticals Neutral Do analysts rate ARDS or VRPX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aridis Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Virpax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility & risk, ARDS or VRPX? Aridis Pharmaceuticals has a beta of 12.15, indicating that its share price is 1,115% more volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Is ARDS or VRPX more profitable? Aridis Pharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Aridis PharmaceuticalsN/A N/A N/A Virpax Pharmaceuticals N/A -1,554.34%-338.29% SummaryAridis Pharmaceuticals beats Virpax Pharmaceuticals on 4 of the 7 factors compared between the two stocks. Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDS vs. The Competition Export to ExcelMetricAridis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5K$821.10M$5.75B$9.56BDividend YieldN/A4.84%4.53%4.07%P/E RatioN/A1.1430.4425.14Price / SalesN/A25.73391.6287.40Price / CashN/A19.5637.0358.50Price / BookN/A6.619.006.20Net Income-$30.37M-$4.93M$3.26B$265.38M7 Day PerformanceN/A2.04%1.00%-1.13%1 Month PerformanceN/A2.65%4.23%-0.70%1 Year PerformanceN/A8.10%28.45%18.99% Aridis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDSAridis PharmaceuticalsN/A$0.00-50.0%N/AN/A$5KN/A0.0030VRPXVirpax PharmaceuticalsN/A$0.01flatN/A-100.0%$14KN/A0.007SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009High Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120Options VolumeCMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002News CoverageGNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070CALACalithera Biosciences0.6426 of 5 stars$0.00flatN/A-98.4%$5KN/A0.0060STABStatera BiopharmaN/A$0.00flatN/AN/A$5KN/A0.0020News CoverageAMPEAmpio PharmaceuticalsN/A$0.00flatN/A+575.0%$3KN/A0.0020PXMDPaxMedicaN/A$0.00flatN/AN/A$2KN/A0.002 Related Companies and Tools Related Companies VRPX Alternatives SCPS Alternatives EVLO Alternatives CMRA Alternatives GNCAQ Alternatives GNCA Alternatives CALA Alternatives STAB Alternatives AMPE Alternatives PXMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARDS) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aridis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access